Assorted News from the Last Week: Brain cancer in children is notoriously hard to treat – a new mRNA cancer vaccine triggers an attack from
Assorted News from the Last Week: Congratulations to CAC2 Supporting Organization Day One Biopharmaceuticals. The FDA has granted accelerated approval to tovorafenib (Ojemda) for the
Assorted News from the Last Week: To achieve successful socioeconomic reintegration in the long term, it is crucial to implement a childhood cancer survivorship program
By CAC2 Student Member Joshua Omale As I reflect on my journey as a childhood cancer advocate here in Nigeria, I’m continually reminded of the
Assorted News from the Last Week: The UK’s National Institute for Health and Care Excellence (NICE) recommended Novartis’ autologous CAR T-cell therapy Kymriah (tisagenlecleucel) for
CAC2 Board Members invited CAC2 members, associate members, student members, and supporting organizations to our Spring CAC2 All-Member Webinar. The Board encourages you to watch
Assorted News from the Last Week: FDA announced its Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee will meet virtually on 22 May to
Assorted News from the Last Week: Cancer is far more likely to be caused by “tumor-suppressor” genes than by one gene run amok. Interestingly, last
Assorted News from the Last Week: The White House Office of Science and Technology Policy (OSTP) has announced that the Pediatric Cancer Data Commons (PCDC)
Author: Bethany Lieberman: March 19, 2024, marks World Social Work Day. Today, we sincerely thank all social workers, especially pediatric cancer social workers, who profoundly
